Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
11 NC counties are under alert, including Johnston County.
Program
On WRAL at 6 : Unhealthy ingredients in kids' food. 5 On Your Side reveals the findings of a local scientist who researched hundreds of products from local shelves.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
57.63
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
September 20, 2024
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed...
Via
Benzinga
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
NASDAQ:SNY may be ready to breakout.
August 12, 2024
Will SANOFI-ADR breakout?
Via
Chartmill
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued.
September 10, 2024
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
Exposures
Product Safety
Why Sanofi Stock Was Robustly Healthy Today
September 03, 2024
Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.
Via
The Motley Fool
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
September 03, 2024
Sanofi's phase 3 HERCULES study data shows tolebrutinib met the primary endpoint in delaying disability progression in non-relapsing secondary progressive multiple sclerosis.
Via
Benzinga
European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday?
September 02, 2024
Global markets started September cautiously, with thin trading volumes as U.S. stock markets were closed for the Labor Day holiday.
Via
Benzinga
Topics
Energy
Exposures
Fossil Fuels
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
August 24, 2024
Don't be too quick to jump on the Wall Street bandwagon.
Via
The Motley Fool
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
August 20, 2024
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...
Via
Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
August 19, 2024
Its 12-month relative strength performance is impressive, but Novavax now faces resistance.
Via
Investor's Business Daily
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
August 19, 2024
SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
August 16, 2024
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
August 15, 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.
Via
InvestorPlace
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
August 14, 2024
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Via
Investor's Business Daily
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
August 09, 2024
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,...
Via
Benzinga
Exposures
Product Safety
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
August 08, 2024
Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to...
Via
Benzinga
Exposures
COVID-19
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
August 08, 2024
Sanofi's phase 3 GMMG-HD7 study reveals that Sarclisa, combined with lenalidomide, bortezomib, and dexamethasone, significantly prolongs progression-free survival in newly diagnosed multiple myeloma...
Via
Benzinga
Where Will Novavax Be in 5 Years?
August 03, 2024
Its been a good year so far for the biotech, but how long can it keep the momentum going?
Via
The Motley Fool
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
August 01, 2024
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...
Via
Benzinga
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
July 31, 2024
Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets.
Via
InvestorPlace
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
July 30, 2024
Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns.
Via
InvestorPlace
Sanofi (SNY) Q2 2024 Earnings Call Transcript
July 25, 2024
SNY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
July 25, 2024
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.
Via
Benzinga
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
July 25, 2024
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.
Via
Benzinga
Topics
Economy
Exposures
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.